A new large-scale study, co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators, provides the strongest evidence yet that a shorter, standard-dose course radiation treatment is equally as effective as conventional radiotherapy for prostate cancer, without compromising patient safety.
A Mayo Clinic study published in the New England Journal of Medicine demonstrates that an off-the-shelf, dual-antibody therapy can generate deep and durable responses in extramedullary multiple myeloma—one of the most aggressive and treatment-resistant forms of the disease.
